7月22日，科伦博泰生物盘中上涨3.03%，报527.0港元，成交额1.44亿港元。
消息面上，近期多家国际投行密集上调公司目标价，摩根大通将目标价由535港元上调至648港元，高盛上调至582.95港元并维持"买入"评级，均看好核心产品sac-TMT的全球商业化前景。高盛将sac-TMT在1L NSCLC研究的成功率由81%上调至90%，并上调公司盈利预测。与此同时，汇添富等多家头部公募机构密集增持港股创新药标的，科伦博泰生物获增持后公募持股比例已触及5%举牌线，机构长线资金持续流入强化市场信心。此前公司核心产品TROP2 ADC联合帕博利珠单抗一线治疗PD-L1阴性NSCLC的III期研究已达主要终点，奠定基本面支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.